![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ASB11 |
Gene summary for ASB11 |
![]() |
Gene information | Species | Human | Gene symbol | ASB11 | Gene ID | 140456 |
Gene name | ankyrin repeat and SOCS box containing 11 | |
Gene Alias | ASB11 | |
Cytomap | Xp22.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q7Z670 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140456 | ASB11 | HCC1 | Human | Liver | HCC | 7.77e-09 | 4.14e-01 | 0.5336 |
140456 | ASB11 | HCC2 | Human | Liver | HCC | 1.30e-15 | 1.02e+00 | 0.5341 |
140456 | ASB11 | HCC5 | Human | Liver | HCC | 3.25e-10 | 7.16e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASB11 | SNV | Missense_Mutation | c.859N>T | p.Leu287Phe | p.L287F | Q8WXH4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A24U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
ASB11 | SNV | Missense_Mutation | rs752677085 | c.537N>A | p.Met179Ile | p.M179I | Q8WXH4 | protein_coding | tolerated(0.53) | possibly_damaging(0.446) | TCGA-BH-A0EB-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ASB11 | SNV | Missense_Mutation | c.803N>T | p.Ala268Val | p.A268V | Q8WXH4 | protein_coding | tolerated(0.45) | probably_damaging(0.999) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
ASB11 | insertion | Frame_Shift_Ins | novel | c.713_714insTCAGAAAGAAAGGAAATCAATGTAT | p.Gln238HisfsTer24 | p.Q238Hfs*24 | Q8WXH4 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
ASB11 | deletion | Frame_Shift_Del | c.95delN | p.Leu32TrpfsTer4 | p.L32Wfs*4 | Q8WXH4 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
ASB11 | insertion | In_Frame_Ins | novel | c.578_579insAACAACCAAAGG | p.Val193_Pro194insThrThrLysGly | p.V193_P194insTTKG | Q8WXH4 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ASB11 | insertion | Frame_Shift_Ins | novel | c.577_578insGATTTTATATGCTGTGTATATTCAC | p.Val193GlyfsTer69 | p.V193Gfs*69 | Q8WXH4 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ASB11 | insertion | Frame_Shift_Ins | rs770804405 | c.68_69insT | p.Phe24LeufsTer2 | p.F24Lfs*2 | Q8WXH4 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
ASB11 | SNV | Missense_Mutation | c.697C>A | p.His233Asn | p.H233N | Q8WXH4 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
ASB11 | deletion | Frame_Shift_Del | c.95delT | p.Leu32TrpfsTer4 | p.L32Wfs*4 | Q8WXH4 | protein_coding | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |